Key facts
- This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 May 2023, 18:59.
Christopher Downs - 28 Apr 2023 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CNSP
- Reported as of
- 28 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 May 2023, 18:59:47 UTC
- Prior SEC filing
- 18 Apr 2023
- Next SEC filing
- 23 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Downs
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 01 May 2023.
Change
- Previous filing in this sequence was filed on 18 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNSP
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +521
- Change %
- +5.6%
- Price
- Shares after
- 9,772
- Date
- 28 Apr 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNSP
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -521
- Change %
- -1.8%
- Price
- Shares after
- 28,248
- Date
- 28 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 521
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.